|
|
 |
|
Viewing report
|
|
|
|
MDV3100 Raises Hopes for Medivation
GlobalData, Nov 2011, Pages: 5
MDV3100 Raises Hopes for Medivation
Summary
GlobalData, the industry analysis specialist, has released its new report, “MDV3100 Raises Hopes for Medivation”. The report is an essential source of information and analysis on why MDV3100 is a hope for Medivation to earn revenues. The report provides insights on the treatment options available for castration resistant prostate cancer (CRPC) and how MDV3100 is superior to the existing and recently approved therapies for CRPC. The report provides insights on the increasing research and development expenses of Medivation and its sources of income till date. This report is built using data and information sourced from proprietary databases, secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key deals, Phase III trial interim results and other ongoing trials of MDV3100. Its scope includes -
- The chrmotherapy drugs available for CRPC patients.
- The interim results of Phase III trials of MDV3100 for CRPC.
- The drugs in developmental pipeline of Medivation.
- The various deals that are a source of revenue for Medivation.
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Understand the potential of MDV3100 as a promising drug that will change the way CRPC is treated.
- Leverage the opportunity and make investment decisions related to MDV3100 or Medivation/
- Formulate effective marketing strategies by understanding the unique advantage MDV3100 has over the existing marketed drugs for CRPC.
- Organize your sales and marketing efforts by identifying how MDV3100 caters to the unmet need present in CRPC therapeutics Market.
|
|
|
|
